pemphigus
Conditions
Interventions
Experimental group 1:before rituximab
Experimental group 2:after rituximab
Control group (Healthy people):None
Sponsors
Dermatology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Patients who meet the diagnostic criteria for pemphigus (a: clinical manifestations of skin, mucous membrane flaccid blisters, erosion, Nissl sign positive; b histopathological examination showed intraepidermal blisters and acantholysis; c direct immunofluorescence examination showed acanthocyte IgG, C3 reticular deposition); 2) adult patients aged 18-80 years; 3) moderate to severe pemphigus (PDAI (Pemphigus Disease Area Index) score, >= 25 points); 4) the first RTX treatment; 5) signed informed consent; 6) can be treated and followed up as planned;
Exclusion criteria
Exclusion criteria: Patients who had previously received RTX or RTX for treatment of relapse; patients with medication contraindications, including severe cardiovascular disease, severe liver and kidney damage, severe active infection, previous severe infusion reactions, history of severe allergy to related drugs, history of cancer, pregnant and lactating women, and recently vaccinated or planned vaccination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptome expression; | — |
Countries
China
Contacts
Public ContactYongfeng Chen
Dermatology Hospital of Southern Medical University
Outcome results
None listed